Description
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-2; some of its antinociceptive and analgesic activities stems from its ability to also activate and desensitize transient receptor potential ankyrin 1 (TRPA1) channels. Etodolac also exhibits anticancer and chemopreventive activities, decreasing incidence of intraductal papillary carcinoma in vivo. Etodolac induces cell cycle arrest and inhibits growth in hepatocellular carcinoma cells, increasing expression of p21 and p27 and decreasing expression of CDK2, CDK4, Cdc2, cyclin A, and cyclin B1. Etodolac also displays radical scavenging activity in vitro.
References
Wang S, Dai Y, Kogure Y, et al. Etodolac activates and desensitizes transient receptor potential ankyrin 1. J Neurosci Res. 2013 Dec;91(12):1591-8. PMID: 24027177.
Adachi T, Tajima Y, Kuroki T, et al. Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters. Carcinogenesis. 2008 Apr;29(4):830-3. PMID: 18296437.
Fernandes E, Costa D, Toste SA, et al. In vitro scavenging activity for reactive oxygen and nitrogen species by nonsteroidal anti-inflammatory indole, pyrrole, and oxazole derivative drugs. Free Radic Biol Med. 2004 Dec 1;37(11):1895-905. PMID: 15528048.
Cheng J, Imanishi H, Liu W, et al. Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines. Cancer Sci. 2004 Aug;95(8):666-73. PMID: 15298730.
